INICIO

Continuation of the Revista Mexicana de Cardiología

  • Home
  • Instructions for authors
    • Instructions for authors
    • Regulations for the publication of supplements
  • Publish
  • Directory
  • Publications
    • Current issue                  
    • All issues
  • About Us
    • About the Journal            
    • Publisher Policies
    • Previous Titles
    • Editorial Management
  • Contact





2022, Number 4

Cardiovasc Metab Sci 2022; 33 (4)

Residual mitral regurgitation grade 2+ after transcatheter edge-to-edge mitral valve repair: Epic fail?

García-Villarreal, Ovidio A

ABSTRACT

Cardiac surgery and interventional cardiology have been pursuing the idea of working together to build a critical process for patients, from which an appraisal is made of long-term procedural outcomes. The sole intention is to avoid therapies which fail to solve the pivotal issues of clinical significance to patient well-being. One such example is the efficacy of transcatheter edge-to-edge mitral valve repair (TEER) in treating the functional mitral regurgitation (FMR), a critical parameter being the presence of post procedural residual, or recurrent mitral regurgitation (MR). The impact that this has in relation to the patient's survival, mortality, and rehospitalization for heart failure rates, should be emphasized before making any special assumptions. Roughly half of patients after TEER experienced post procedural MR 2+ (grade 2/4 by echocardiography) within the first year. In fact, the aforementioned has been greatly ignored in the current guidelines for valvular heart disease, giving a recommendation Class IIa for TEER in FMR. Therefore, whether MR 2+ after TEER influences the patient post procedural outcome in the short and longer terms, requires careful consideration.
  FULL TEXT PDF  

Keywords

functional mitral regurgitation mitral valve mitral valve insufficiency mitral valve repair transcatheter edge-to-edge mitral valve repair




  • Send manuscript
  • Instructions for authors
  • Recent
  • TOP 5

  • 2023, Vol.34, Núm. S1
  • Welcome
    2023, Vol.34, Núm. S1
  • Effectiveness and safety of amphepramone in a slow release as part of the...
    2007, Vol.18, Núm. 1
  • Long QT syndrome secondary to drug interaction between hydroxychloroquine and...
    2018, Vol.29, Núm. 2
  • Etiology and pathophysiology of type 2 diabetes mellitus
    2011, Vol.22, Núm. 1
  • Official Mexican Standard NOM-030-SSA2-2009. For the prevention, detection,...
    2011, Vol.22, Núm. 3
  • Early repolarization. Normal or dangerous?
    2011, Vol.22, Núm. 3


Cardiovascular and Metabolic Science Vol. 33, Num. 4, Octubre-Diciembre 2022. Es una publicación trimestral editada por la Asociación Nacional de Cardiólogos de México. Magdalena 135. Col. Del Valle. Del. Benito Juárez. Ciudad de México, México. C.P. 03103. Tel. 5556368002 https://www.cardiovascularandmetabolicscience.org.mx/ ancam@ancam.org.mx Editor responsable. Dr. Eduardo Meaney Mendiolea. Reserva de Derechos al Uso Exclusivo Nº 04-2019-061316491900-203. ISSN: 2683-2828 versión impresa y 2954-3835 versión electrónica. Ambos otorgados por el Instituto Nacional del Derecho de Autor. Responsable de la última actualización de este número, Departamento de Internet, Graphimedic, S.A. de C.V., Ing. Luis Rosales Jiménez, Coquimbo 936, Col. Lindavista, Delegación Gustavo A. Madero, C.P. 07300, Ciudad de México, México. Fecha de última modificación, 22 de marzo de 2023.

 

2023     |     https://www.cardiovascularandmetabolicscience.org.mx/